Register for our free email digests:
Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Advanz Has Six Deals In The Works As It Cuts Its Losses
Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.
Bortezomib Boom Benefits Stada But Pemetrexed Position Proves Perplexing
Launching the oncology drug bortezomib in 14 European countries helped Stada to record an 11% increase in both Generics and group sales in the first half of 2019. But the German group, which is about to start rolling out biosimilar teriparatide, has suffered a legal setback on pemetrexed in its home market.
Sagent Slides To A Loss, Dragging Down Nichi-Iko’s Margin
An operating loss recorded by its US Sagent affiliate depressed Nichi-Iko’s group operating margin to just 3.7%, even though the Japanese generics specialist’s turnover increased by a tenth on strong domestic generics demand.
Lupin Q1 Profit Up 50% But Regulatory Overhang, Slow Product Scale-Up Sparks Concern
Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.
Perrigo Remains Committed To Splitting Off Prescription Despite Delay
Perrigo has pushed back plans to split off its Prescription business as part of its transformation into a consumer self-care focused company.
Aurobindo Expects Sandoz Completion ‘Very Soon’
Aurobindo Pharma says its billion-dollar purchase of Sandoz’s US business is on track for completion “very soon” as it announced net first-quarter net profit that rocketed by nearly 40%, powered by strong US sales.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.